Post-earnings recap
Reported
Thu, May 14, 2026
EPS actual
$0.43
EPS est.
$0.34
EPS surprise
+24.64%
1-day move
+5.73%
CorMedix Inc. reported better-than-expected earnings per share, which is a positive sign for the company. However, the stock saw a slight decline of 0.12%, indicating that investors may have been looking for more clarity on revenue performance or future guidance. The lack of revenue results and management commentary could have contributed to the muted stock reaction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.43 | $0.33 | +24.64% |
| Revenue | — | $105M | — |
No transcript is on record, and the analysis is based solely on numerical results.
CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with unmet medical needs. Operating in the health care sector, its work is particularly relevant as the demand for effective treatments continues to grow.
Last quarter
In Q4-2025, CorMedix reported an EPS of $0.16, significantly missing the estimate of $0.86, leading to a notable stock decline. This follows a strong performance in Q3-2025 where they exceeded expectations with an EPS of $1.26.
EPS beat streak
2Q
EPS beat rate
88%
Avg EPS surprise
+38.23%
Avg 1-day reaction
-3.67%
Analysts expect CorMedix to report an EPS of $0.33 and revenue of $105M for Q1-2026, reflecting cautious optimism after a mixed performance in previous quarters.
Bull case
If CorMedix meets or exceeds the EPS and revenue expectations, it could signal a strong recovery and renewed investor confidence, potentially driving the stock higher.
Bear case
Conversely, if the company fails to meet these expectations, particularly after a significant miss last quarter, it could lead to further declines in stock price.
Key metrics to watch
EPS
$0.33Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$105MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the EPS meet the consensus estimate of $0.33?
This figure is crucial for assessing the company's profitability and could significantly influence investor sentiment.
Q2
What revenue figures will CorMedix report, and how do they compare to the $105M consensus?
Revenue performance will provide insights into market demand and the effectiveness of the company's sales strategies.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Why consensus could be wrong
The Street may be overly cautious given the recent EPS miss, but the strong performance in Q3-2025 suggests a potential for recovery that isn't fully reflected in current estimates.
Supporting evidence
The options market is pricing a 14.31% move, which is lower than the historical average of 17.05%, indicating potential underestimation of volatility.
CorMedix has a strong EPS beat rate of 88%, suggesting a higher likelihood of exceeding expectations.
Key risk
If the company reports an EPS significantly above $0.33, it could challenge the current cautious sentiment.
Pre-commit to what would confirm each case.
The market is closely watching these earnings due to the mixed results from previous quarters, making this report pivotal for future investor confidence.
Bull confirmed if
Achieving an EPS of $0.33 or better would confirm the bull case and signal a strong recovery.
Bear confirmed if
An EPS below $0.33 would reinforce concerns about the company's profitability and growth prospects.
What the market is pricing for the move.
Implied Move
±14.31%
Historical Avg
±15.2%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±14.3% while CRMD has averaged ±15.2% over the last 8 prints — setup is roughly in line with history.
ATM IV
1.8%
30d HV
36.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If CorMedix beats expectations, history suggests a modest positive reaction, potentially confirming a turnaround in performance.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss could lead to a significant decline, as history indicates an average drop of around -11.52% following disappointing results.
The lines on the call that would change the story.